Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma

Jae-Woo Jung; Hae-Sim Park; Choon-Sik Park; Sang-Heon Cho; Inseon S. Choi; Hee-Bom Moon; Soon Seog Kwon; Ho Joo Yoon; Jung Won Park; Jong-Myung Lee; Dong-Chull Choi; Byoung Whui Choi

doi:10.3904/kjim.2020.549.e1

Korean J Intern Med > Volume 36(5); 2021 > Article

Jung, Park, Park, Cho, Choi, Moon, Kwon, Yoon, Park, Lee, Choi, and Choi: Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma

Erratum

Korean J Intern Med 2021;36(5):1260-1260.

Published online: September 1, 2021

DOI: https://doi.org/10.3904/kjim.2020.549.e1

Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma

Jae-Woo Jung^1,^*, Hae-Sim Park^2,^*, Choon-Sik Park³, Sang-Heon Cho⁴, Inseon S. Choi⁵, Hee-Bom Moon⁶, Soon Seog Kwon⁷, Ho Joo Yoon⁸, Jung Won Park⁹, Jong-Myung Lee¹⁰, Dong-Chull Choi¹¹, Byoung Whui Choi^1,¹²

¹Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea

²Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea

³Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea

⁴Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

⁵Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea

⁶Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

⁷Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea

⁸Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea

⁹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

¹⁰Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea

¹¹Division of Allergy, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

¹²Department of Internal Medicine, Chung-Ang University H.C.S. Hyundae Hospital, Namyangju, Korea

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

This corrects the article "Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma" in volume 36 on page 1001.

In the article cited above, there was an error in Figure 3B. A corrected version of Figure 3B is attached.

We apologize for any inconvenience that this may have caused.

Figure 3.

Korean asthma control test (K-ACT) at week 0, 16, and 24. (A) Mean ± standard error of the mean K-ACT. (B) Asthma control levels. K-ACT was improved after omalizumab treatment, and the proportions of “partly controlled” and “controlled” on week 16 and week 24 were higher than those at week 0. ^ap < 0.001, ^bp < 0.005 compared to K-ACT at week 0.

TOOLS

METRICS

0 Crossref
0 Scopus
1,326 View
90 Download

Related articles

Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma2021 July;36(4)

Editorial Office: 101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6792 Fax: +82-2-790-0993 E-mail: kaim@kams.or.kr